Data for Pfizer’s Monthly Injectable GLP-1 Drug Pave Way for Broad Phase 3 Plan in Obesity
A monthly injectable GLP-1 drug from Pfizer’s $10 billion Metsera acquisition is now on track for a Phase 3 program spanning 10 pivotal studies this year. While Pfizer’s pipeline spans internally developed and in-licensed assets for other targets, the pharma company says the Metsera drug is the foundation for its obesity strategy pursuing monotherapies and combination treatments.
Stop Treating Patches Like They’re Riskier Than Ransomware
We’re losing the patching battle and therefore the ransomware war. Here's how healthcare can change its perspective, improve patching, and better block ransomware pathways.
How AI and Predictive Analytics Will Shape EMS, Fire, and Healthcare in 2026
AI and analytics offer a path forward that prioritizes smarter workflows, coordination between teams, and better visibility into system performance. The organizations best positioned will be the ones that invest in responsible innovation, interoperability, and tools that make a difference in their daily work.
How One Leading DSO Used Analytics to Drive a 26% Increase in Crown Treatment Planning Rates
A recent webinar, sponsored by Overjet, offered insights from Affinity Dental Management executives on how AI-driven clinical intelligence software can transform dental service organizations.
The 4 Biotech Companies on Track to IPO this Week Despite the Government Shutdown
Across all industries, the total number of companies on track to go public could make this week the most active for IPOs since 2021. Despite the partial government shutdown, there are paths biotechs can pursue to the public markets.